Therefore, our result of MEK and FLT3 inhibitors on AML provides proof-of-concept that drug combinations can be readily tested using the zebrafish platform, enabling quick assessment of efficacy and potential toxicity to the organism can be evaluated. This evidence concerns the gene FLT3 and acute myeloid leukemia.